Chemours faces suit

2026-10-12

Class Action Lawsuit Filed Against Chemours for Misleading Investors on Product Demand and Financial Guidance.

Schall, Brown & Schwartz LLP filed a class action lawsuit against Chemours, alleging misleading claims about Opteon product demand and 2026 financial guidance. Shareholders purchasing shares between F

Pluang · 2026-10-12 06:10 UTC · 2 media covered

2026-10-11

Chemours Faces Securities Lawsuit Over Disclosures and Guidance

Chemours Co faces a securities class action lawsuit concerning Opteon demand and 2026 financial guidance disclosures. While investors view the stock as undervalued at $13.61 versus an $18.56 fair valu

Simply Wall Street · 2026-10-11 18:11 UTC

2026-10-09

Chemours Company Faces Securities Fraud Class Action Over Opteon Demand Claims

A securities fraud class action lawsuit alleges Chemours made misleading statements regarding Opteon product demand, causing a stock drop. Investors have until December 7, 2026, to file lead plaintiff

Business Wire · 2026-10-09 20:11 UTC · 2 media covered

Media coverage (3)

Class Action Lawsuit Filed Against Chemours for Misleading Investors on Product Demand and Financial Guidance.Pluang
Chemours Faces Securities Lawsuit Over Disclosures and GuidanceSimply Wall Street
Chemours Company Faces Securities Fraud Class Action Over Opteon Demand ClaimsBusiness Wire

Chemours faces suit

Class Action Lawsuit Filed Against Chemours for Misleading Investors on Product Demand and Financial Guidance.

Chemours Faces Securities Lawsuit Over Disclosures and Guidance

Chemours Company Faces Securities Fraud Class Action Over Opteon Demand Claims

Media coverage (3)

Related topics